Delamanid is a nitro-dihydro-imidazooxazole compound that inhibits mycolic acid synthesis in Mycobacterium tuberculosis, used as a component of optimised background regimens for multidrug-resistant tuberculosis. Simson Pharma's Delamanid reference standard and impurities support QC for this critical reserve TB agent.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Delamanid Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.